Thrombotic Complications of Low‐Dose Versus High‐Dose Four‐Factor Prothrombin Complex Concentrate for Massive Bleeding in Pediatric Cardiovascular Surgery
Pediatric Anesthesia · 2025-08 · 35 (8) · 619-626
DOI: 10.1111/pan.15118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Anesthesia, online erschienen am 28.05.2025. Verfasst von Laura Palacio-Guzmán und 4 weiteren Autor:innen. Beteiligte Einrichtung: Anesthesiology Department, Fundación Valle del Lili, Cali, Colombia. Hauptthemen laut MEDLINE: Thrombosis, Blood Coagulation Factors, Cardiovascular Surgical Procedures, Postoperative Hemorrhage. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Introduction
Major bleeding is a life‐threatening complication in pediatric cardiovascular surgery, particularly in neonates and infants with immature coagulation systems and congenital heart defects ( CHD ). Cardiopulmonary bypass ( CPB ) exacerbates these risks by depleting coagulation factors and platelets. Four‐factor prothrombin complex concentrates ( 4F ‐ PCC ) provide targeted hemostatic correction but carry potential thrombotic risks.
Methods
Among 1296 pediatric patients who underwent cardiovascular surgery between January 2018 and April 2024, a retrospective cohort study analyzed 104 patients who received 4F ‐ PCC . Patients were grouped into low‐dose (< 35 U/kg) and high‐dose (≥ 35 U/kg). Thrombotic complications were evaluated within 15 days after use.
Results
The median age was 1 month ( IQR : 0–7.5), and 69.23% of patients were male. Common diagnoses included hypoplastic left heart syndrome (14.42%), ventricular septal defect (13.46%), and coarctation of the aorta (12.5%). Frequent procedures included Norwood procedure (14.42%) and ventricular septal defect closure (13.46%). Thrombotic complications occurred in 6.73% overall, with no significant differences between high‐dose (5.26%) and low‐dose (8.51%) groups ( p = 0.698). High‐dose 4F ‐ PCC was associated with shorter CPB times ( p = 0.007) (Cohen's d 0.537) but higher reintervention rates (57.89% vs. 34.04%; p = 0.015) (Cramér's V 0.118).
Conclusion
High‐dose 4F ‐ PCC was not associated with increased thrombotic complications. Thrombotic complications in this study were inferior to all‐cause thrombotic complications in pediatric cardiovascular surgery of 11%. These findings support 4F ‐ PCC as a viable option for managing severe bleeding in pediatric cardiovascular surgery. Further studies should explore dose optimization and preventive applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anesthesiology Department, Fundación Valle del Lili, Cali, Colombia.
- Universidad Icesi, Facultad de Medicina, Cali, Colombia.
- Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.
ORCID-Profile: Sergio Alzate-Ricaurte, Gustavo Adolfo Cruz-Suarez
Zitieren
APA
Palacio-Guzmán, L., Alzate-Ricaurte, S., Plata-Ayala, N., Pombo-Jiménez, A., & Cruz-Suarez, G. A. (2025). Thrombotic Complications of Low‐Dose Versus High‐Dose Four‐Factor Prothrombin Complex Concentrate for Massive Bleeding in Pediatric Cardiovascular Surgery. Pediatric Anesthesia, 35(8), 619-626. https://doi.org/10.1111/pan.15118
Vancouver
Palacio-Guzmán L, Alzate-Ricaurte S, Plata-Ayala N, Pombo-Jiménez A, Cruz-Suarez GA. Thrombotic Complications of Low‐Dose Versus High‐Dose Four‐Factor Prothrombin Complex Concentrate for Massive Bleeding in Pediatric Cardiovascular Surgery. Pediatric Anesthesia. 2025;35(8):619-626. doi:10.1111/pan.15118
BibTeX
@article{PalacioGuzmn2025,
author = {Palacio-Guzmán, Laura and Alzate-Ricaurte, Sergio and Plata-Ayala, Natalia and Pombo-Jiménez, Andres and Cruz-Suarez, Gustavo Adolfo},
title = {Thrombotic Complications of Low‐Dose Versus High‐Dose Four‐Factor Prothrombin Complex Concentrate for Massive Bleeding in Pediatric Cardiovascular Surgery},
journal = {Pediatric Anesthesia},
year = {2025},
volume = {35},
number = {8},
pages = {619--626},
doi = {10.1111/pan.15118}
}
EUVIMED